Boston Scientific‘s trial, which will enroll 128 patients across 28 sites in the US, will assess rates of device- and/or procedure-related major adverse events and patency rates at nine months.

The EPIC Stent is designed to sustain vessel patency, while providing improved visibility and accuracy during placement.

The stent uses a Radial Tandem Architecture, which is designed to provide stent flexibility while maintaining predictable radial force characteristics throughout the entire stent size matrix.